Press Release

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief …

[Read more...] about Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

-Shareholders Equity Deficiency has been Cured - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market BOSTON and LONDON, November 19, 2024 …

[Read more...] about Akari Therapeutics Regains Full Nasdaq Compliance

- Secures $3.2m in PIPE Financing - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit BOSTON and LONDON, November 14, 2024 (GLOBE …

[Read more...] about Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies …

[Read more...] about Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger

BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company …

[Read more...] about Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger